https://ir.acurxpharma.com/presentations The latest news released by Acurx Pharmaceuticals, Inc. en-us Equisolve https://d1io3yog0oux5.cloudfront.net/_54f3e0bf8d6456169cd25706f74b6503/acurxpharma/logo.png https://www.acurxpharma.com 88 31 https://ir.acurxpharma.com/presentations/detal/2895/in-vitro-activity-of-the-novel-antibacterial-acx-362e-against-clostridioides-difficile Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/2895/in-vitro-activity-of-the-novel-antibacterial-acx-362e-against-clostridioides-difficile https://ir.acurxpharma.com/presentations/detal/2896/time-kill-kinetics-of-the-novel-antibacterial-agent-acx-362e-against-clostridioides-difficile Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/2896/time-kill-kinetics-of-the-novel-antibacterial-agent-acx-362e-against-clostridioides-difficile https://ir.acurxpharma.com/presentations/detal/2897/id-week-oral-presentation-of-phase-1-data-presented-by-dr-kevin-garey-professor-chair-department-of-pharmacy-practice-and-translational-research-university-of-houston Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/2897/id-week-oral-presentation-of-phase-1-data-presented-by-dr-kevin-garey-professor-chair-department-of-pharmacy-practice-and-translational-research-university-of-houston https://ir.acurxpharma.com/presentations/detal/2905/dna-polymerase-iiic-inhibitor-ibezapolstat-first-of-a-new-class-of-antibiotics-with-a-novel-mechanism-of-action-clinical-trial-update Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/2905/dna-polymerase-iiic-inhibitor-ibezapolstat-first-of-a-new-class-of-antibiotics-with-a-novel-mechanism-of-action-clinical-trial-update https://ir.acurxpharma.com/presentations/detal/2933/poster-presentation-and-abstract-from-id-week-october-2021-titled-an-open-label-phase-2a-study-of-ibezapolstat-a-unique-gram-positive-selective-spectrum-gpss-antibiotic-for-patients-with-clostridioides-difficile-infection-presented-by-dr-kevin-garey-professor-and-chair-university-of-houston-college-of-pharmacy Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/2933/poster-presentation-and-abstract-from-id-week-october-2021-titled-an-open-label-phase-2a-study-of-ibezapolstat-a-unique-gram-positive-selective-spectrum-gpss-antibiotic-for-patients-with-clostridioides-difficile-infection-presented-by-dr-kevin-garey-professor-and-chair-university-of-houston-college-of-pharmacy https://ir.acurxpharma.com/presentations/detal/2976/poster-presentation-id-week-october-2022-investigating-the-gram-positive-selective-spectrum-of-ibezapolstat-a-first-in-class-dna-polymerase-iiic-pol-iiic-inhibitor Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/2976/poster-presentation-id-week-october-2022-investigating-the-gram-positive-selective-spectrum-of-ibezapolstat-a-first-in-class-dna-polymerase-iiic-pol-iiic-inhibitor https://ir.acurxpharma.com/presentations/detal/2975/id-week-presentation-october-2022-development-update-on-ibezapolstat-for-the-treatment-of-clostridioides-difficile-infection-focus-on-the-microbiome Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/2975/id-week-presentation-october-2022-development-update-on-ibezapolstat-for-the-treatment-of-clostridioides-difficile-infection-focus-on-the-microbiome https://ir.acurxpharma.com/presentations/detal/2984/poster-presentation-eccmid-april-2023-by-dr-kevin-garey-titled-novel-pharmacology-and-susceptibility-of-ibezapolstat-against-clostridioides-difficile-isolates-with-reduced-susceptibility-to-c-difficile-directed-antibiotics Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/2984/poster-presentation-eccmid-april-2023-by-dr-kevin-garey-titled-novel-pharmacology-and-susceptibility-of-ibezapolstat-against-clostridioides-difficile-isolates-with-reduced-susceptibility-to-c-difficile-directed-antibiotics https://ir.acurxpharma.com/presentations/detal/2983/eccmid-presentation-by-robert-j-deluccia-executive-chairman-copenhagen-april-2023 Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/2983/eccmid-presentation-by-robert-j-deluccia-executive-chairman-copenhagen-april-2023 https://ir.acurxpharma.com/presentations/detal/2997/world-antimicrobial-resistance-conference-presentation Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/2997/world-antimicrobial-resistance-conference-presentation https://ir.acurxpharma.com/presentations/detal/3003/id-week-presentation-dr-kevin-garey-gram-positive-selective-spectrum-activity-of-ibezapolstat-october-2023 Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/3003/id-week-presentation-dr-kevin-garey-gram-positive-selective-spectrum-activity-of-ibezapolstat-october-2023 https://ir.acurxpharma.com/presentations/detal/3004/id-week-presentation-by-dr-michael-silverman-and-dr-kevin-garey-ibezapolstat-october-2023 Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/3004/id-week-presentation-by-dr-michael-silverman-and-dr-kevin-garey-ibezapolstat-october-2023 https://d3ua9t66dzwd8a.cloudfront.net/HC24/p_50099_Acurx.mp3 Thu, 16 Apr 2026 07:49:05 -0400 https://d3ua9t66dzwd8a.cloudfront.net/HC24/p_50099_Acurx.mp3 https://ir.acurxpharma.com/presentations/detal/3010/golf-coast-consortia-amr-conference-presentation-of-ph2b-comparative-microbiology-and-microbiome-data-by-dr-kevin-garey-et-al-january-2024 Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/3010/golf-coast-consortia-amr-conference-presentation-of-ph2b-comparative-microbiology-and-microbiome-data-by-dr-kevin-garey-et-al-january-2024 https://ir.acurxpharma.com/presentations/detal/3076/presentation-by-kevin-gareypharmdmsfidsaprofessorandchairuniversityofhoustoncollegeof-pharmacy-at-escmid-april-2024-entitled-efficacy-and-safety-of-ibezapolstat-compared-with-vancomycin-for-the-treatment-ofclostridioides-difficileinfection-a-phase-2-randomized-double-blind-study Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/3076/presentation-by-kevin-gareypharmdmsfidsaprofessorandchairuniversityofhoustoncollegeof-pharmacy-at-escmid-april-2024-entitled-efficacy-and-safety-of-ibezapolstat-compared-with-vancomycin-for-the-treatment-ofclostridioides-difficileinfection-a-phase-2-randomized-double-blind-study https://ir.acurxpharma.com/presentations/detal/3080/presentation-anaerobe-conference-2024-garey-phase-2-microbiome-data Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/3080/presentation-anaerobe-conference-2024-garey-phase-2-microbiome-data https://ir.acurxpharma.com/presentations/detal/3082/smits-presentation-at-icds-conference-september-2024-structure-of-the-replicative-polymerase-polc-in-complex-with-the-anti-cdi-agent-ibezapolstat-and-a-related-inhibitor Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/3082/smits-presentation-at-icds-conference-september-2024-structure-of-the-replicative-polymerase-polc-in-complex-with-the-anti-cdi-agent-ibezapolstat-and-a-related-inhibitor https://ir.acurxpharma.com/presentations/detal/3083/presentation-at-icds-conference-september-2024-microbiome-results-from-the-phase-2-randomized-double-blind-study-of-ibezapolstat-compared-with-vancomycin-for-the-treatment-of-clostridioides-difficileinfection Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/3083/presentation-at-icds-conference-september-2024-microbiome-results-from-the-phase-2-randomized-double-blind-study-of-ibezapolstat-compared-with-vancomycin-for-the-treatment-of-clostridioides-difficileinfection https://ir.acurxpharma.com/presentations/detal/3088/presentation-by-dr-kevin-garey-at-the-peggy-lillis-foundation-inaugural-cdi-scientific-symposium-with-phase-2-clinical-trial-update Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/3088/presentation-by-dr-kevin-garey-at-the-peggy-lillis-foundation-inaugural-cdi-scientific-symposium-with-phase-2-clinical-trial-update https://ir.acurxpharma.com/presentations/detal/3102/poster-presentation-by-mia-urem-ph-d-leiden-university-medical-center-a-unique-inhibitor-conformation-selectively-targets-dna-polymerase-polc-of-gram-positive-priority-pathogens Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/3102/poster-presentation-by-mia-urem-ph-d-leiden-university-medical-center-a-unique-inhibitor-conformation-selectively-targets-dna-polymerase-polc-of-gram-positive-priority-pathogens https://ir.acurxpharma.com/presentations/detal/3103/presentation-by-mia-urem-ph-d-leiden-university-medical-center-machines-on-genes-2025 Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/3103/presentation-by-mia-urem-ph-d-leiden-university-medical-center-machines-on-genes-2025 https://ir.acurxpharma.com/presentations/detal/3094/corporate-presentation-dated-september-2025 Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/3094/corporate-presentation-dated-september-2025 https://ir.acurxpharma.com/presentations/detal/3109/id-week-presentation-october-2025-by-michael-h-silverman-md-facp-and-kevin-garey-pharmd-ms Thu, 16 Apr 2026 07:49:05 -0400 https://ir.acurxpharma.com/presentations/detal/3109/id-week-presentation-october-2025-by-michael-h-silverman-md-facp-and-kevin-garey-pharmd-ms